Clinical Trial Update: A Phase Ⅱ Clinical Trial of Recombinant Corona Virus Disease-19 (COVID-19) Vaccine (Sf9 Cells) [Phase 2]

View source ↗

Summary

Phase 2 trial update for a recombinant COVID-19 vaccine produced in Sf9 cells has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Coronavirus Disease 2019

Drugs mentioned

• Recombinant Corona Virus Disease-19 (COVID-19) Vaccine (Sf9 Cells)

Snippet

Sponsor: Jiangsu Province Centers for Disease Control and Prevention | Conditions: COVID-19 | Phase 2 | Status: COMPLETED